Connect with us

Heartland

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer See Official Release HereNEW YORK, Jan. 14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading […]

The post MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience appeared first on CannabisFN.

Republished by Plato

Published

on

Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer

See Official Release HereNEW YORK, Jan. 14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA.

MindMed Co-CEO J.R. Rahn said, “Rob has been an integral advisor to MindMed on Project Lucy and in preparing our meetings with the FDA, and we are honored he is now joining us on the senior leadership team. We are excited to attract such top tier talent from the psychedelic drug development community. The entire MindMed team is looking forward to exploring potential additional programs evaluating psilocybin and other psychedelics backed by Rob’s recent experience and expertise gaining a breakthrough therapy designation at FDA for a psychedelic assisted therapy.”

Robert Barrow Bio:

Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in CNS conditions such as multiple sclerosis, Alzheimer’s Disease and Parkinson’s Disease. Mr. Barrow holds a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.

About MindMed
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic-inspired medicines to improve health, promote wellness and alleviate suffering. The company’s has initiated or is initiating studies to evaluate potential treatments to help patients with ADHD, anxiety, cluster headaches and substance abuse. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:MMQ. For more information: www.mindmed.co.‍MindMed Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of Mind Medicine (MindMed) Inc. (“MindMed”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying word. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for  Products; unforeseen safety issues resulting from the administration of  Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting  Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies  on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.

Source: https://www.cannabisfn.com/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience/

Heartland

CBD hash I bought gives off an extremely strange smell. Is this bad hash? More details in the comments!

Republished by Plato

Published

on

CBD hash I bought gives off an extremely strange smell. Is this bad hash? More details in the comments! submitted by /u/Threwaway1105
[link] [comments]

Source:

Continue Reading

Heartland

100 Million Dollar Cannabis Bank Fraud, House Bill 1420, & Mexico’s Accredited Postgrad MMJ Program

Republished by Plato

Published

on

100 Million Dollar Cannabis Bank Fraud, House Bill 1420, & Mexico's Accredited Postgrad MMJ Program submitted by /u/Infinity_Broadcast
[link] [comments]

Source:

Continue Reading

Heartland

Republished by Plato

Published

on

Source:

Continue Reading
Heartland2 days ago

CBD Vape Oil Market 2021: Global Trends, Business Overview, Challenges, Opportunities …

Heartland4 days ago

Uncategorized5 days ago

What CBD Oil is Right For Me?

Heartland5 days ago

CBD Oil for Beginners

Heartland4 days ago

Heartland4 days ago

Heartland5 days ago

Registration opens for consumable hemp manufacturers and retailers

Heartland3 days ago

Industrial Hemp in Automotive Market Estimated Forecast Analysis 2021-2030

Material2 days ago

Microstructure, characterization of interfacial phases and mechanical properties of high Nb–TiAl/Al2O3 joints brazed by novel Nb particle-reinforced Ag–Cu filler alloy

Heartland2 days ago

Drew Carey CBD – How Does It Work For Body Pain

Heartland5 days ago

CBD Skincare Products Are Popping Up Everywhere — But Do They Actually Work?

Heartland5 days ago

CBP Can't Block Parts Imports, Hemp Machinery Co. Says

Heartland4 days ago

Heartland4 days ago

8 of the best cannabis gummies to try right now

Heartland3 days ago

National Hemp Association Awards First Recipients of Social Equity Conscious Business (SECB …

Heartland5 days ago

Thc causes me anxiety will cbd be fine? I have the tincture but nervous to try it also how much mg of cbd should i start with for a first dose?

Heartland4 days ago

Sunnyvale Labs CBD Gummies — Instant Pain Relief Hemp Gummies!

Heartland4 days ago

Acreage Holdings to Sell Florida Cannabis Operations to Red White & Bloom for $60 Million

Heartland4 days ago

Heartland4 days ago

Heartland5 days ago

Material5 days ago

IMC microstructure modification and mechanical reinforcement of Sn–Ag–Cu/Cu microelectronic joints through an advanced surface finish technique

Material5 days ago

A new approach of predicting dynamic recrystallization using directly a flow stress model and its application to medium Mn steel

Heartland5 days ago

Hemp Is Creating an EcoRevolution

Heartland5 days ago

CBD to combat physcoactive properties in THC

Heartland4 days ago

Heartland4 days ago

How CBD Can Help You Live A Healthy Lifestyle, With Medical Marijuana Management Team …

Uncategorized4 days ago

The Daily Hit: The February 25th, 2021

Uncategorized5 days ago

Boston Cannabis Lawyer

Uncategorized5 days ago

Canopy Growth Corp. Receives Double Sell Rating From Jeffries and Eight Capital

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America